Last reviewed · How we verify
Brenetafusp and pembrolizumab — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Brenetafusp and pembrolizumab (Brenetafusp and pembrolizumab) — Immunocore Ltd.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Brenetafusp and pembrolizumab TARGET | Brenetafusp and pembrolizumab | Immunocore Ltd | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Brenetafusp and pembrolizumab CI watch — RSS
- Brenetafusp and pembrolizumab CI watch — Atom
- Brenetafusp and pembrolizumab CI watch — JSON
- Brenetafusp and pembrolizumab alone — RSS
Cite this brief
Drug Landscape (2026). Brenetafusp and pembrolizumab — Competitive Intelligence Brief. https://druglandscape.com/ci/brenetafusp-and-pembrolizumab. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab